Magyar onkologia最新文献_第5页

[he importance of mTOR hyperactivity and RICTOR amplification, and the associated targeted therapy possibilities in malignant tumours]. 【mTOR过度活跃和RICTOR扩增的重要性，以及恶性肿瘤中相关的靶向治疗可能性】。

Magyar onkologia Pub Date : 2023-09-28 Epub Date: 2023-09-13

Fatime Szalai, Ildikó Krencz, Dorottya Moldvai, Gábor Petővári, Titanilla Dankó, Noémi Nagy, Gergő Papp, Judit Pápay, Anna Sebestyén, Dániel Sztankovics

{"title":"[he importance of mTOR hyperactivity and RICTOR amplification, and the associated targeted therapy possibilities in malignant tumours].","authors":"Fatime Szalai, Ildikó Krencz, Dorottya Moldvai, Gábor Petővári, Titanilla Dankó, Noémi Nagy, Gergő Papp, Judit Pápay, Anna Sebestyén, Dániel Sztankovics","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Failures of anti-tumour therapies and drug resistance initiate difficulties in cancer treatments often caused by alterations in signalling network activity, including PI3K/Akt/mTOR hyperactivity due to oncogenic mutations. In this review, we summarise the relevance of mTOR (mechanistic target of rapamycin) dysregulation identified decades ago, which is now known to be characteristic of many tumours. In this context, we present differences in activity, function and testability of mTOR kinase complexes (mTORC1 and mTORC2) differing in structure, regulatory mechanisms and inhibitor sensitivity. We highlight that genetic alterations, including RICTOR amplification and associated mTOR hyperactivity, are relevant in targeted therapy development. It is recommended to investigate mTOR profile activity in patients for whom mTOR inhibitor therapies are considered since the current first-generation mTOR inhibitors (rapamycin and analogues) may be ineffective in case of mTORC2 hyperactivity. Ongoing phase trials of new inhibitors and combination therapies are promising in advanced stage patients selected by molecular markers.</p>","PeriodicalId":94127,"journal":{"name":"Magyar onkologia","volume":"67 3","pages":"165-180"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41176039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Surgery of peritoneal surface malignancies - surgical cytoreduction and hyperthermic intraperitoneal chemotherapy]. [腹膜表面恶性肿瘤的外科手术-外科细胞减少和腹膜内热疗化疗]。

Magyar onkologia Pub Date : 2023-09-28 Epub Date: 2023-09-12

Gergely Huszty, László Bihari, László Gráf, Attila Szijártó, Szabolcs Máté

引用次数: 0

[Potential role of type I interferon in the genetic progression of melanoma]. [I 型干扰素在黑色素瘤遗传进展中的潜在作用]。

Magyar onkologia Pub Date : 2023-09-28 Epub Date: 2023-08-18

Laura Vízkeleti, Andrea Ladányi, Orsolya Papp, Viktória Doma, Sarolta Kárpáti, Erzsébet Rásó, Tamás Barbai, József Tímár

引用次数: 0

[Farnesyltransferase inhibitors have antitumoral effects in mutant KRAS containing cancer cells in preclinical models]. [法尼基转移酶抑制剂在临床前模型中对含有突变 KRAS 的癌细胞具有抗肿瘤作用]。

Magyar onkologia Pub Date : 2023-09-28 Epub Date: 2023-08-21

Marcell Baranyi, Balázs Hegedűs, Eszter Molnár, József Tóvári, Ivan Ranđelović, András Perczel, László Buday, György Keserű, József Tímár

引用次数: 0